We demonstrate that increased GATA2 levels are disadvantageous to CEBPADM leukemic cells and that this can be counteracted by TET2 loss thus providing an explanation for the co-occurrence of CEBPA and TET2 lesions in AML. Here, GATA2 is linked to acute myeloid leukemia.